Taking dolutegravir in the morning may avert insomnia
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds
Trans women wary of antiretroviral drug and hormone interactions
Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease
Boosted darunavir plus lamivudine matches three-drug regimen
VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment
Long-acting NRTI shows promise for HIV treatment and PrEP
First protease inhibitor combination pill maintains viral suppression
